Results 211 to 220 of about 35,617 (253)

Effects of sodium-glucose co-transporter-2 inhibitors on the risk of nephrolithiasis and urinary tract infections in Thai patients with type 2 diabetes: a hospital-based cohort study. [PDF]

Diabetol Metab Syndr
Lukkunaprasit T, Tansawet A, Siriyotha S, Looareesuwan P, Yang J, Kunakorntham P, Sirisreetreerux P, Anothaisintawee T, McKay GJ, Attia J, Thakkinstian A.   +10 more
europepmc   +1 more source

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near. [PDF]

Front Pediatr
Portalatin GM, Hong-McAtee I, Burgner AM, Gould ER, Hunley TE.   +4 more
europepmc   +1 more source

Effects of sodium-glucose co-transporter-2 inhibitors on body composition and liver fat markers in non-alcoholic fatty liver disease: a narrative review. [PDF]

Ann Med Surg (Lond)
Fawwad SH, Patel MS, Dziugieł S, Alfaki R, Tamoor Akhtar Shaikh M, Khanal K, Lamichhane P, Barali S.   +7 more
europepmc   +1 more source

Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the "right drug" and the "right dose" for dogs. [PDF]

J Vet Med Sci
Umezawa M, Fujii Y, Orito K, Yoshimoto R.   +3 more
europepmc   +1 more source

Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Serum Chloride Concentrations in Patients with Heart Failure. [PDF]

J Cardiovasc Dev Dis
Jurin I, Ivanović Mihajlović V, Šakić Z, Pavlov M, Šipić T, Vitlov P, Falak H, Grizelj D, Manola Š, Udovičić M.   +9 more
europepmc   +1 more source

Sodium glucose co-transporter 2 inhibitors safety depending on their adverse drug reactions and glucose monitoring parameters in type 2 diabetes mellitus.

Indian J Pharmacol
Bellapu D, Darwin R.
europepmc   +1 more source

Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity

openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sodium‐glucose co‐transporter 2 inhibitors and hematopoiesis

Journal of Cellular Physiology, 2022
AbstractMany patients with diabetes mellitus, especially those with chronic kidney disorders, have some degree of anemia due to a spectrum of causes and underlying pathophysiologic pathways. As such, enhancement in erythropoiesis is important in these patients.
Habib Yaribeygi, Mina Maleki, Fatemeh Nasimi, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar   +5 more
openaire   +2 more sources

Sodium–glucose co-transporter-2 inhibitors

2022
Abstract This chapter studies the use of aldosterone antagonists, also known as Mineralocorticoid Receptor Antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction (LVSD) — now called heart failure with reduced ejection fraction (HF-REF) — have ...
Matthew M. Y. Lee, Kieran F. Docherty, Pardeep S. Jhund   +2 more
openaire   +1 more source

The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors

New Zealand Medical Journal, 2022
The sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure ...
Chok G, Chan, Ralph, Stewart
openaire   +2 more sources